Previous 10 | Next 10 |
In Conjunction with His Appointment, Mr. Wambeke Purchased $750,000 of Common Shares from DiaMedica in a Private Placement Priced Above Market DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemi...
2023-03-29 10:01:02 ET DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Conference Call March 29, 2023, 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Offi...
2023-03-28 16:32:13 ET DiaMedica Therapeutics press release ( NASDAQ: DMAC ): FY GAAP EPS of -$0.52 in-line. Total cash, cash equivalents and investments of $33.5 million, current liabilities of $2.2 million and working capital of $31.7 million as of December 31, 2022, com...
Conference Call and Webcast March 29 at 8:00 am Eastern Time / 7:00 am Central Time Company has had Ongoing and Successful Communications with the FDA to Address the Clinical Hold Company Completed Part 1 of In-Use Study, Results Support Proposed ReMEDy2 Dose Revision ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33 rd...
DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the app...
DiaMedica Therapeutics press release ( NASDAQ: DMAC ): Q3 GAAP EPS of -$0.12 beats by $0.03 . Total cash, cash equivalents and investments of $36.1M. For further details see: DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03
Company to Conduct In-Use Study to Address FDA Latest Information Request Cash Runway Into Q4 2024 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological d...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alph...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. Th...